Invention Grant
![Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide](/docs/US/2019-09-24/US10420764B2/abs.jpg.600x600.jpg)
- Patent Title: Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide
-
Application No.: US15183088Application Date: 2016-06-15
-
Publication No.: US10420764B2Publication Date: 2019-09-24
- Inventor: Noel Alan Weldon Baker , Alpesh Mistry
- Applicant: AstraZeneca AB
- Applicant Address: SE Sodertalje
- Assignee: AstraZeneca AB
- Current Assignee: AstraZeneca AB
- Current Assignee Address: SE Sodertalje
- Main IPC: A61K31/496
- IPC: A61K31/496 ; A61K47/24 ; A61K9/46 ; A61K9/20 ; A61K9/16
![Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide](/abs-image/US/2019/09/24/US10420764B2/abs.jpg.150x150.jpg)
Abstract:
There are provided pharmaceutical compositions comprising a compound of Formula (I) as defined herein and an amount of an alkaline effervescent agent that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.
Public/Granted literature
Information query
IPC分类:
